1. Home
  2. UVV vs NTLA Comparison

UVV vs NTLA Comparison

Compare UVV & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UVV
  • NTLA
  • Stock Information
  • Founded
  • UVV 1886
  • NTLA 2014
  • Country
  • UVV United States
  • NTLA United States
  • Employees
  • UVV N/A
  • NTLA N/A
  • Industry
  • UVV Farming/Seeds/Milling
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • UVV Industrials
  • NTLA Health Care
  • Exchange
  • UVV Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • UVV 1.3B
  • NTLA 1.2B
  • IPO Year
  • UVV N/A
  • NTLA 2016
  • Fundamental
  • Price
  • UVV $54.50
  • NTLA $11.30
  • Analyst Decision
  • UVV
  • NTLA Buy
  • Analyst Count
  • UVV 0
  • NTLA 19
  • Target Price
  • UVV N/A
  • NTLA $35.11
  • AVG Volume (30 Days)
  • UVV 315.4K
  • NTLA 4.5M
  • Earning Date
  • UVV 08-06-2025
  • NTLA 08-07-2025
  • Dividend Yield
  • UVV 6.02%
  • NTLA N/A
  • EPS Growth
  • UVV N/A
  • NTLA N/A
  • EPS
  • UVV 3.78
  • NTLA N/A
  • Revenue
  • UVV $2,947,284,000.00
  • NTLA $45,569,000.00
  • Revenue This Year
  • UVV N/A
  • NTLA N/A
  • Revenue Next Year
  • UVV N/A
  • NTLA N/A
  • P/E Ratio
  • UVV $14.42
  • NTLA N/A
  • Revenue Growth
  • UVV 7.23
  • NTLA N/A
  • 52 Week Low
  • UVV $49.05
  • NTLA $5.90
  • 52 Week High
  • UVV $67.33
  • NTLA $24.16
  • Technical
  • Relative Strength Index (RSI)
  • UVV 40.14
  • NTLA 49.41
  • Support Level
  • UVV $53.08
  • NTLA $11.17
  • Resistance Level
  • UVV $55.10
  • NTLA $12.31
  • Average True Range (ATR)
  • UVV 1.01
  • NTLA 0.87
  • MACD
  • UVV 0.01
  • NTLA -0.26
  • Stochastic Oscillator
  • UVV 36.13
  • NTLA 11.92

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: